Research Papers:
Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3349 views | HTML 2687 views | ?
Abstract
Jun Deng1,*, Wan Lei1, Xiaojun Xiang1, Ling Zhang1, Jun Lei1, Yu Gong1, Meijiao Song1, Yi Wang1, Ziling Fang1, Feng Yu1, Miao Feng1, Ze Sun1, Jun Chen1, Zhengyu Zhan1, Jianping Xiong1
1Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, PR China
*The first author
Correspondence to:
Jianping Xiong, e-mail: [email protected]
Keywords: CUL4A, Hippo, miR-9, miR-137, gastric cancer
Received: September 05, 2015 Accepted: December 07, 2015 Published: January 28, 2016
ABSTRACT
Although Cullin 4A (CUL4A) is mutated or amplified in several human cancer types, its role in gastric cancer (GC) and the mechanisms underlying its regulation remain largely uncharacterized. In the present study, we report that the expression of CUL4A significantly correlated with the clinical stage of the tumor and lymph node metastasis, and survival rates were lower in GC patients with higher levels of CUL4A than in patients with lower CUL4A levels. The upregulation of CUL4A promoted GC cell proliferation and epithelial-mesenchymal transition (EMT) by downregulating LATS1-Hippo-YAP signaling. Knocking down CUL4A had the opposite effect in vitro and in vivo. Interestingly, CUL4A expression was inhibited by the microRNAs (miRNAs), miR-9 and miR-137, which directly targeted the 3′-UTR of CUL4A. Overexpression of miR-9 and miR-137 downregulated the CUL4A-LATS1-Hippo signaling pathway and suppressed GC cell proliferation and invasion in vitro. Taken together, our findings demonstrate that perturbations to miR-9/137-CUL4A-Hippo signaling contribute to gastric tumorigenesis, and suggest potential therapeutic targets for the future treatment of GC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7048